BR0112100A - Método de tratamento de doenças vasculares periféricas, neuropatias periféricas e neuropatias autonÈmicas - Google Patents

Método de tratamento de doenças vasculares periféricas, neuropatias periféricas e neuropatias autonÈmicas

Info

Publication number
BR0112100A
BR0112100A BR0112100-6A BR0112100A BR0112100A BR 0112100 A BR0112100 A BR 0112100A BR 0112100 A BR0112100 A BR 0112100A BR 0112100 A BR0112100 A BR 0112100A
Authority
BR
Brazil
Prior art keywords
neuropathies
peripheral
autonomic
treatment
peripheral vascular
Prior art date
Application number
BR0112100-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Ralph E Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0112100A publication Critical patent/BR0112100A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR0112100-6A 2000-06-30 2001-06-29 Método de tratamento de doenças vasculares periféricas, neuropatias periféricas e neuropatias autonÈmicas BR0112100A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21506500P 2000-06-30 2000-06-30
US21902900P 2000-07-18 2000-07-18
PCT/US2001/041202 WO2002002118A1 (en) 2000-06-30 2001-06-29 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies

Publications (1)

Publication Number Publication Date
BR0112100A true BR0112100A (pt) 2003-05-20

Family

ID=26909649

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112100-6A BR0112100A (pt) 2000-06-30 2001-06-29 Método de tratamento de doenças vasculares periféricas, neuropatias periféricas e neuropatias autonÈmicas

Country Status (13)

Country Link
EP (1) EP1303279A1 (ja)
JP (1) JP2004511433A (ja)
KR (1) KR20030047907A (ja)
CN (1) CN1440287A (ja)
AU (1) AU2001279275A1 (ja)
BR (1) BR0112100A (ja)
CA (1) CA2414352A1 (ja)
HU (1) HUP0301451A3 (ja)
IL (1) IL153426A0 (ja)
MX (1) MXPA03000033A (ja)
NZ (1) NZ523108A (ja)
PL (1) PL365565A1 (ja)
WO (1) WO2002002118A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020588D0 (en) * 2000-08-21 2000-10-11 Pfizer Ltd Treatment of wounds
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
WO2004082667A1 (en) * 2003-03-17 2004-09-30 Pfizer Products Inc. Treatment of type 1 diabetes with pde5 inhibitors
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
EP1838319B1 (en) * 2005-01-07 2018-03-07 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders

Also Published As

Publication number Publication date
CA2414352A1 (en) 2002-01-10
HUP0301451A2 (hu) 2003-09-29
NZ523108A (en) 2005-04-29
CN1440287A (zh) 2003-09-03
MXPA03000033A (es) 2003-09-25
EP1303279A1 (en) 2003-04-23
IL153426A0 (en) 2003-07-06
PL365565A1 (en) 2005-01-10
AU2001279275A1 (en) 2002-01-14
KR20030047907A (ko) 2003-06-18
JP2004511433A (ja) 2004-04-15
HUP0301451A3 (en) 2004-10-28
WO2002002118A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
Mavissakalian et al. Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
GB0410266D0 (en) Treatment of apoptosis
TW200607509A (en) Use of optically pure (S,S) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
Maragh et al. Disabling pansclerotic morphea: clinical presentation in two adults
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
Colglazier et al. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil.
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
Moschella et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin
Haynes et al. Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case report.
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
BR0112100A (pt) Método de tratamento de doenças vasculares periféricas, neuropatias periféricas e neuropatias autonÈmicas
Tramèr et al. Magnesium Bier's block for treatment of chronic limb pain: a randomised, double-blind, cross-over study
CO5251425A1 (es) Metodo y composiciones para administrar taxanos oralmente a pacientes humanos
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
RU2007112409A (ru) Одновременный прием тигициклина и дигоксина
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
Samitz et al. Oral florid papillomatosis: response to aminopterin
Gertner Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome
HUP0204097A2 (hu) Guanozin-3',5'-monofoszfát-foszfodiészteráz inhibitorok alkalmazása diabetikus fekélyek kezelésére szolgáló készítmények előállítására
Yamaura et al. Recurrent ventricular tachyarrhythmias associated with QT prolongation following hydrofluoric acid burns
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009.